Elevate Semiconductor的动态

Member spotlight @Benjamin Smith, NextRNA Therapeutics "The most valuable part about being a LabOps member is connecting with other members of the lab ops community and learning from their experience how best to run a lab." Why Join LabOps Unite? 1. Connect instantly with over 1300 other LabOps Professionals from all over the world. 2. It is Free. 3. It is Vendor Agnostic - have discussions with your peers without being bombarded with sales calls or pitches. Our member platform allows you to get answers to your questions in real-time. 4. Advance your career through mentorship. 5. Educational Content - We host monthly webinars, host a leadership conference and connect you with your local chapter to make sure you are up-to-date on everything LabOps Unite. 6. Connect to industry standards - we are defining the industry standards for a LabOps Career, stay connected to our research and impact with partners like MassBio’s Bioversity Program https://lnkd.in/eJyAfJnk #labopsunite #joinus #leadership #biotech #pharma #LabOpsUnite

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Biopharma’s 20 highest-paid CEOs of 2023, earning $20M+ pay packages: The best-paid CEOs of 2023 fall largely into two groups: They’re either running some of the world’s biggest drugmakers, or they were given huge incentive packages in their first year on the job or as head of a newly-public company. Endpoints News reviewed hundreds of annual proxy filings across biopharma. This is the first article in a series examining CEO and employee pay trends, after analyzing over 500 CEO pay packages last year. Like our analysis of 2022 pay packages, the top 20 CEOs brought in paydays valued at over $20 million. The top-paid list has its staples in pharma giant CEOs like Amgen’s Bob Bradway, Pfizer’s Albert Bourla, and Eli Lilly’s David Ricks. But it also has some smaller biotechs dishing out equally hefty awards at startups like Neumora Therapeutics, Arcellx, and Vir Biotechnology. As in years past, Endpoints used the estimated fair value of newly-issued shares and stock options. This tracks how much a company’s board decided to pay its top leader in the past year, whereas other methods better approximate a CEO’s take-home pay by calculating the value of cashed-in or vested equity instead. Those stock awards, however, are typically granted years ago. Here are 2023’s highest-paid CEOs. #1: Acelyrin former CEO Shao-Lee Lin — $88,678,569 Shao-Lee Lin The highest-paid biopharma CEO of 2023 — on paper — was Shao-Lee Lin, the former CEO of Acelyrin. The immunology startup raised over half a billion dollars in the industry’s largest IPO of 2023, and shortly thereafter awarded its founder Lin a correspondingly large pay package. Following its public debut, the board hired a consultancy that determined Lin’s pay was in the bottom quartile compared to CEOs of other biopharmas that recently IPO’d. In particular, the firm found the value of Lin’s equity holdings lagged behind this peer group. The board’s compensation committee subsequently granted a one-time supplemental award in August 2023. One-third of that equity were shares that would vest over time, while two-thirds of the stock was contingent on its stock performance and company goals, like regulatory submissions and commercial readiness. This is where Lin’s potential fortune remains only on paper. After awarding that equity package, Acelyrin’s lead drug candidate failed a late-stage study last September, sending its stock into a tailspin. Lin stepped down as CEO this May, and the board stated her performance-based stock awards — which made up the vast majority of her reported 2023 pay — would be forfeited in their entirety. Lin’s severance included a $1 million lump sum payment, accelerated vesting by 18 months on her outstanding equity, and an extension in exercising stock options through March 31, 2025.… #lucidquest #genetherapy #celltherapy

Gene&Cell Therapy >> Biopharma’s 20 highest-paid CEOs of 2023, earning $20M+ pay packages: The best-paid CEOs of 2023 fall largely into two groups: They’re either running some of the world’s biggest drugmakers, or they were given huge incentive packages in their first year on the job or as head of a newly-public company. Endpoints News reviewed hundreds of annual proxy filings across biopharma. This is the first article in a series examining CEO and employee pay trends, after analyzing over 500 CEO pay packages last year. Like our analysis of 2022 pay packages, the top 20 CEOs brought in paydays valued at over $20 million. The top-paid list has its staples in pharma giant CEOs like Amgen’s Bob Bradway, Pfizer’s Albert Bourla, and Eli Lilly’s David Ricks. But it also has some smaller biotechs dishing out equally hefty awards at startups like Neumora Therapeutics, Arcellx, and Vir Biotechnology. As in years past, Endpoints used the estimated fair value of newly-issued shares and stock options. This tracks how much a company’s board decided to pay its top leader in the past year, whereas other methods better approximate a CEO’s take-home pay by calculating the value of cashed-in or vested equity instead. Those stock awards, however, are typically granted years ago. Here are 2023’s highest-paid CEOs. #1: Acelyrin former CEO Shao-Lee Lin — $88,678,569 Shao-Lee Lin The highest-paid biopharma CEO of 2023 — on paper — was Shao-Lee Lin, the former CEO of Acelyrin. The immunology startup raised over half a billion dollars in the industry’s largest IPO of 2023, and shortly thereafter awarded its founder Lin a correspondingly large pay package. Following its public debut, the board hired a consultancy that determined Lin’s pay was in the bottom quartile compared to CEOs of other biopharmas that recently IPO’d. In particular, the firm found the value of Lin’s equity holdings lagged behind this peer group. The board’s compensation committee subsequently granted a one-time supplemental award in August 2023. One-third of that equity were shares that would vest over time, while two-thirds of the stock was contingent on its stock performance and company goals, like regulatory submissions and commercial readiness. This is where Lin’s potential fortune remains only on paper. After awarding that equity package, Acelyrin’s lead drug candidate failed a late-stage study last September, sending its stock into a tailspin. Lin stepped down as CEO this May, and the board stated her performance-based stock awards — which made up the vast majority of her reported 2023 pay — would be forfeited in their entirety. Lin’s severance included a $1 million lump sum payment, accelerated vesting by 18 months on her outstanding equity, and an extension in exercising stock options through March 31, 2025. #2: Royalty Pharma CEO Pablo Legorreta — $84,837,077… #lucidquest #genetherapy #celltherapy

I always relish the opportunity to take the digital stage for our global colleagues at Exyte at our Global Town Hall Meeting. The digital event provides the perfect opportunity for dialogue, as our colleagues globally can participate in the event and share their thoughts, ideas, and questions. Although the event takes place digitally, the participants' energy and enthusiasm were palpable. During the event, I had the chance to touch on our recently announced planned acquisition of Kinetics, a leading global provider of installation services and equipment for high-tech industries such as semiconductors, biopharma, and batteries. The acquisition will expand Exyte's offerings and will solidify our position as a global provider of complex solutions for high-tech industries. I also touched on Exyte's Leadership Principles, emphasizing how they are integral to Exyte's "Next Level" agenda, ensuring that leadership behavior aligns with company goals, values, and core competencies. Among other major topics, the executive board discussed operational excellence in project delivery at Exyte, a topic that is important to our clients and us and is crucial for Exyte's success. Operational excellence is something we live by at Exyte. It implies that success in projects is a shared responsibility regardless of hierarchy, departments, or functions, and is fueled by collaboration. Operational excellence is something that all employees need to collectively continue to strive for to truly deliver nothing short of excellence to our clients.

The evolutions at Bayer are truly spectacular by what is happening and what apparently is being promised will happen. Whether you're riding high with a blockbuster product or navigating through the competitive waters of a saturated market where competitors abound, or again a poor pipeline of new products, both products and manufacturers alike share common drivers and needs. First and foremost, there's the imperative to meticulously assess the efficacy of our current processes, governance and mindsets/ capabilities, whether they're propelling us forward or holding us back. This understanding forms the bedrock upon which meaningful change can be built. Next comes the pursuit of enhancing efficiency and effectiveness, vital for not just surviving but thriving amidst fierce competition. To outshine our rivals – be they products or organizations – requires a commitment to continuous improvement and innovation. But it's not just about making changes; it's about embedding them deeply into the fabric of our operations and culture to ensure their longevity and impact. This necessitates the right blend of organizational structures, streamlined processes, and a culture that embraces and drives change, led by the leadership team with relentless dedication. At The OSICS Network, transformation isn't just a buzzword; it's what we live and breathe. Through our global network of seasoned professionals, we've not only understood these challenges but have delivered tangible results that transcend borders. So, let's start a conversation. It costs nothing to explore how we can help elevate your organization and its people. But it could very well be the most valuable conversation you have. Reach out to : [email protected] https://lnkd.in/eqW84CUM

New Post: Why Investors Are Flocking to These 2 Medical Stocks - https://lnkd.in/gbdj7TeM - Given the growing demand for healthcare facilities, rapid integration of digital technology, and transformative biotechnology breakthroughs, the medical industry is poised for continued growth and profitability this year and beyond.... - #news #business #world ----------------------------------------------------- Download: Stupid Simple CMS - https://lnkd.in/g4y9XFgR ----------------------------------------------------- or download at SourceForge - https://lnkd.in/gNqB7dnp

Many great takeaways from the #ASAPSummit Leadership Forum: * C-suites are often circumventing the alliance team when trying to "fix" a partner function that isn't broken, noted Janet Schijns?of JSG? *?“We all use words and we assume everyone knows what we’re talking about. No one asks questions and we’re arrogant," said?Christopher Jones of?AT&T * Cloud solutions helped the healthcare industry innovate during the pandemic, and the use of cloud and AI is still on the rise today, according to?Lynn Richard of?GE HealthCare *?“How do we get the C-suite to embed the strategy and accept that partnering is important?” asked?Cindy Warren of?Johnson & Johnson. By figuring out whether alliance management is "a cost center or a revenue generator, or a core business unit," noted?Sally Wang of?International SOS It's all in Michael Burke's recap of the event. Read it now for the latest trends in partner, ecosystem, and alliance management from partnering leaders around the world:?https://lnkd.in/g58FJBGj #alliancemanagement #alliances #strategicalliances #alliancemanagers #collaboration #strategicpartnerships #partnerships #tech #ITindustry #IT #hightech?#ecosystems #ecosystem #pharmaceutical #pharmaceuticalindustry #biopharma #biotech #biotechnology #biotechindustry #healthcare #CSuite #revenue #revenuegeneration #revenuegenerator?

Aramis Frost our Lead Executive Search consultant here at AL Solutions has been supporting the growth of Global Pharma’s, Hospitals, and emerging Biotech’s in hiring their Senior Leadership teams. While speaking with numerous General Managers, CEOs, CFOs, CMOs, and CSOs, he has gained insight into some of the challenges they have faced on their journeys to success. Below are some tips they wish they had received earlier in their career ?? #biotech #biotechnology #science #research #pharma #lifescience

NEW: Here are the 20 highest-paid CEOs biopharma for 2023. I analyzed proxy filings for over 500 life sciences companies, identifying the boards who awarded their CEOs the most valuable pay packages last year. The list includes pharma giants like Amgen, Pfizer, and AstraZeneca, but also biotech startups like Neumora, Vir Biotechnology, Inc. and Madrigal Pharmaceuticals. Across all the companies, shares and stock options drove the majority of the compensation packages. My latest for Endpoints News — with more to come this week on pay trends across the industry:

Would you fire 1,500 of your employees if it meant your organization might move faster? Bayer, a well-known German pharma company, made 1,500 of its employees redundant last quarter, and they say even more cuts are coming soon. Two-thirds of the employees that were cut were in management positions. Bayer says the reason for this is that they plan to reduce hierarchies and eliminate bureaucracy by removing roles that cause bottlenecks. “Our focus is really relentless on making sure that every job in the company is oriented around the mission.” While I understand that keeping your organization tight and fast is important and we’ve recently seen several such restructurings, I think the balance between empathy for 1,500 people and company efficiency is very hard. What do you think about this balance?